|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Adherex Technologies Inc., of Ottawa, Ontario, entered a screening agreement with the National Cancer Institute in Bethesda, Md., which will evaluate the anticancer effects and vascular-targeting capabilities of compounds from Adherex's library of cadherin antagonists. The institute will assess the selected drug candidates in vitro as well as in preclinical animal models. The classes of agents to be included under the agreement include peptide cadherin antagonist compounds for N-cadherin, E-cadherin, desmogleins, VE-cadherin and OB-cadherin, as well as Adherex's third-generation, small-molecule, non-peptide cadherin antagonists.
o Agouron Pharmaceutical Inc.'s ...